SCHEMBL4352791

SCHEMBL4352791

CCSc1ncc(C(=O)c2cc(F)c(F)cc2OC)c(N)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.49
CDK4 P11802 1/20 0.49
CCND1 P24385 1/20 0.49
CDK2 P24941 1/20 0.49
SMN1; SMN2 Q16637 10/20 0.43
ALDH1A1 P00352 10/20 0.43
HPGD P15428 3/20 0.43
POLB P06746 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
RAB9A P51151 7/20 0.43
NPC1 O15118 6/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 7/20 0.42
LMNA P02545 6/20 0.42
TSHR P16473 4/20 0.42
USP2 O75604 1/20 0.42
HSD17B10 Q99714 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348389 0.92 SMN1; SMN2 (0.44) CDK1CDK4CCND1CDK2SMN1; SMN2
SCHEMBL4352555 0.91 SMN1; SMN2 (0.43) CDK1CDK4CCND1CDK2SMN1; SMN2
SCHEMBL13621473 0.87 CDK1 (0.51) CDK1CDK4CCND1CDK2SMN1; SMN2
SCHEMBL4352506 0.87 CDK1 (0.51) CDK1CDK4CCND1CDK2SMN1; SMN2
SCHEMBL4350576 0.86 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1HPGDPOLBTDP1
SCHEMBL4362491 0.86 CDK1 (0.51) CDK1CDK4CCND1CDK2SMN1; SMN2
SCHEMBL4349357 0.84 CDK1 (0.51) CDK1CDK4CCND1CDK2SMN1; SMN2
SCHEMBL4356448 0.84 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1HPGDPOLBTDP1
SCHEMBL4351863 0.84 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1HPGDPOLBTDP1
SCHEMBL4351161 0.83 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1HPGDPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK1 6/4885CDK4 1/4885CCND1 32/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK1 6/4885CDK4 1/4885CCND1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.